Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

10.86USD
23 Mar 2017
Change (% chg)

$0.15 (+1.40%)
Prev Close
$10.71
Open
$10.70
Day's High
$11.10
Day's Low
$10.69
Volume
2,362,332
Avg. Vol
3,062,149
52-wk High
$38.48
52-wk Low
$10.35

Select another date:

Thu, Mar 23 2017

BRIEF-Valeant CEO's 2016 compensation was $62.7 mln

March 23 Valeant Pharmaceuticals International Inc:

BRIEF-ValuAct reports open market purchse of 500,000 shares of Valeant Pharma

March 16 Valeant Pharmaceuticals International Inc

BRIEF-Valueact Holdings reports 5.2 pct stake in Valeant Pharma

March 16 Valeant Pharmaceuticals International Inc

ValueAct raises its stake in Valeant Pharmaceuticals

March 16 Hedge fund ValueAct Holdings LP raised its stake to 5.2 percent in Valeant Pharmaceuticals International Inc, calling Valeant's shares "undervalued" and saying it intends to continue to discuss with the company to "enhance shareholder value".

BRIEF-Glycyx Pharmaventures and Valeant agree to terms of licensing agreement in oncology

* Glycyx Pharmaventures and Valeant Pharmaceuticals agree to binding terms of licensing agreement in the field of oncology

BRIEF-Valeant's Bausch + Lomb reports introduction of Biotrue Oneday

March 15 Valeant Pharmaceuticals International Inc:

Ackman's Pershing Square sells Valeant stake, takes $3 billion loss

BOSTON Billionaire investor William Ackman walked away from Valeant Pharmaceuticals International Inc on Monday with a loss of more than $3 billion as he sold his entire stake in the struggling drug company after trying to rescue it for some 18 months. | Video

Valeant shares fall as Ackman exit highlights company's challenges

BOSTON Valeant Pharmaceuticals Inc's stock price fell to its lowest level in eight years on Tuesday after the abrupt exit of its biggest supporter put renewed focus on the Canadian company's most pressing problem: raising capital to cut its roughly $30 billion debt pile. | Video

Valeant shares fall as Ackman exit highlights company's challenges

BOSTON, March 14 Valeant Pharmaceuticals Inc's stock price fell to its lowest level in eight years on Tuesday after the abrupt exit of its biggest supporter put renewed focus on the Canadian company's most pressing problem: raising capital to cut its roughly $30 billion debt pile.

Select another date:

More From Around the Web